Enveric Biosciences, Inc. (ENVB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Enveric Biosciences, Inc. (ENVB) Healthcare & Pipeline Overview

Enveric Biosciences, Inc. is a biotechnology company developing cannabinoid-based therapeutics for cancer care and related conditions. Its pipeline focuses on innovative treatments for osteoarthritis, cancer-related distress, mental health indications, and topical skin applications, positioning it within the evolving pharmaceutical landscape.

What Is the Investment Thesis for ENVB?

Enveric Biosciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cannabinoid-based therapeutics for cancer care and related conditions positions it in a rapidly evolving market. Key value drivers include the successful development and commercialization of its pipeline products, particularly EV104, EVM-101, EVM-201, EVM-301, EV102, and EV101. Growth catalysts include positive clinical trial results, regulatory approvals, and strategic partnerships. However, the company faces significant risks, including the uncertainty of clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $0.00B and a P/E ratio of -0.06, Enveric's valuation is highly dependent on its ability to advance its pipeline and secure funding. Investors should carefully consider the risks and potential rewards associated with this early-stage biotechnology company.

Based on FMP financials and quantitative analysis

ENVB Key Highlights

Enveric Biosciences is focused on developing cannabinoid medicines for cancer care.

• The company's product pipeline includes EV104 for osteoarthritis and EVM-101 and EVM-201 for cancer-related distress.
• EVM-301 is being developed for mental health indications.
• EV102 is a cannabinoid cream for topical skin application.
• EV101 is a cannabinoid and chemotherapy combination therapy.

Who Are ENVB's Competitors?

ENVB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ENVB's Key Strengths?

Proprietary cannabinoid-based drug development platform.

• Diverse pipeline of therapeutic candidates targeting multiple indications.
• Experienced management team with expertise in drug development.
• Focus on unmet needs in cancer care and related conditions.

What Are ENVB's Weaknesses?

Limited financial resources and reliance on external funding.

• Early-stage development and high clinical trial risk.
• Small number of employees.
• Dependence on regulatory approvals for commercialization.

What Could Drive ENVB Stock Higher?

Announcement of clinical trial results for EV104 in osteoarthritis.

• Regulatory submissions for EVM-101 and EVM-201 for cancer-related distress.
• Progress in the development of EVM-301 for mental health indications.
• Expansion of strategic partnerships and collaborations.
• Advancements in the development of novel cannabinoid formulations.

What Are the Key Risks for ENVB?

Financial-distress signal — its Altman Z-Score of -20.26 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain positive clinical trial results.
• Regulatory delays or rejection of product approvals.
• Competition from established pharmaceutical companies.
• Dependence on external funding and potential dilution of shareholder value.
• Negative perception of cannabinoid-based therapies.

What Are the Growth Opportunities for ENVB?

• Expansion into New Therapeutic Areas: Enveric Biosciences has the opportunity to expand its pipeline beyond cancer care to address other therapeutic areas where cannabinoids may have potential benefits. This could include neurological disorders, autoimmune diseases, and inflammatory conditions. The market for these indications is substantial, with a global market size estimated at billions of dollars. Successful expansion would require additional research and development efforts, as well as strategic partnerships with experts in these fields. Timeline: 2-5 years.
• Strategic Partnerships and Collaborations: Enveric can accelerate its growth by forming strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers. These collaborations can provide access to new technologies, funding, and market expertise. For example, partnering with a company specializing in drug delivery systems could enhance the bioavailability and efficacy of Enveric's cannabinoid-based therapies. Timeline: Ongoing.
• Advancement of Clinical Trials: The successful advancement of Enveric's pipeline products through clinical trials is crucial for its growth. Positive clinical trial results can lead to regulatory approvals and commercialization, generating significant revenue streams. The company should prioritize its most promising drug candidates and allocate resources to expedite their development. Timeline: Ongoing.
• Geographic Expansion: Enveric has the opportunity to expand its geographic reach beyond the United States to international markets. This could involve establishing partnerships with local distributors or setting up its own operations in key regions. The global market for cannabinoid-based therapeutics is growing rapidly, particularly in Europe and Asia. Timeline: 3-5 years.
• Development of Novel Formulations and Delivery Systems: Enveric can differentiate its products by developing novel formulations and delivery systems that improve their efficacy and patient convenience. This could include developing sustained-release formulations, transdermal patches, or inhaled formulations. The market for innovative drug delivery systems is substantial, with a global market size estimated at billions of dollars. Timeline: 2-4 years.

What Are ENVB's Competitive Advantages?

• Proprietary cannabinoid formulations and drug delivery systems.
• Intellectual property protection through patents and trademarks.
• Expertise in cannabinoid science and drug development.
• Established relationships with researchers and healthcare providers.

What Does ENVB Do?

Enveric Biosciences, Inc., headquartered in Naples, Florida, is a pharmaceutical company dedicated to the development of cannabinoid-based medicines, primarily targeting cancer care and related conditions. The company's mission is centered around creating innovative therapies that address unmet needs in areas such as pain management, mental health, and dermatological conditions. Enveric's product pipeline includes a range of drug candidates, each designed to leverage the therapeutic potential of cannabinoids. These include EV104 for the treatment of osteoarthritis, EVM-101 and EVM-201 for cancer-related distress, EVM-301 for mental health indications, EV102 as a cannabinoid cream for topical skin application, and EV101, a cannabinoid and chemotherapy combination therapy. Founded with the vision of transforming cancer care through cannabinoid science, Enveric Biosciences has strategically built a pipeline of diverse therapeutic candidates. The company is focused on rigorous research and development to advance its products through clinical trials and regulatory approval. Enveric's approach involves combining cannabinoids with other therapeutic agents to enhance efficacy and address specific disease mechanisms. The company aims to establish itself as a leader in the cannabinoid-based pharmaceutical space, offering innovative solutions for patients and healthcare providers.

What Products and Services Does ENVB Offer?

• Develop cannabinoid medicines for cancer care.
• Research and develop treatments for osteoarthritis.
• Create therapies for cancer-related distress.
• Develop medications for mental health indications.
• Formulate cannabinoid creams for topical skin applications.
• Combine cannabinoids with chemotherapy for enhanced cancer treatment.

How Does ENVB Make Money?

• Develop and patent novel cannabinoid-based therapies.
• Conduct preclinical and clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved products through partnerships or direct sales.

What Industry Does ENVB Operate In?

Enveric Biosciences operates within the biotechnology industry, which is characterized by rapid innovation, high regulatory scrutiny, and significant investment in research and development. The market for cannabinoid-based therapeutics is growing as research reveals the potential therapeutic benefits of cannabinoids for various conditions, including pain, anxiety, and neurological disorders. Enveric competes with other biotechnology and pharmaceutical companies developing similar therapies, as well as established players in the pain management and mental health markets. The company's success depends on its ability to differentiate its products, navigate the regulatory landscape, and secure funding for clinical trials and commercialization.

Who Are ENVB's Key Customers?

• Patients suffering from cancer and related conditions.
• Individuals with osteoarthritis.
• Patients experiencing cancer-related distress.
• Individuals with mental health disorders.
• Patients with skin conditions requiring topical treatment.

The most recent 12 insider filings for Enveric Biosciences, Inc. break down as 0 sales and 12 purchases. On net that is roughly 412K shares acquired (about $0) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Enveric Biosciences, Inc.

Revenue for Enveric Biosciences, Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $3.0M, with diluted EPS of $-0.76. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, ENVB averaged $-2.47 in diluted EPS.

ENVB Valuation & Market Position

Relative to its peer group, ENVB's quantitative score of 30/100 is below the peer average of 70/100.

Enveric Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.26 places it in the distress zone, a signal of elevated financial risk.

Enveric Biosciences, Inc. has beaten Wall Street's EPS estimate in 4 of its last 7 reported quarters — more hits than misses. Reported results have landed about 2503.4% below estimates on average.

Company Profile

Enveric Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Joseph Edward Tucker. ENVB has traded publicly since 2015.

ENVB Financials

ENVB Latest News

ENVB Analyst Consensus

ENVB MoonshotScore

What Investors Ask About Enveric Biosciences, Inc. (ENVB) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources